Among them, PDGFRB-related multitargeted receptor tyrosine kinase inhibitor regorafenib (BAY 73-4506) has been FDA approved for the treatment of metastatic COAD that has progressed after all standard therapies (62). The gene discussed is PDGFRB; the disease is colon adenocarcinoma.